Wuwei Yang

Wuwei Yang

Auto-generated profile, based on publicly available information

Wuwei Yang

Department of Oncology, the Fifth Medical Center of PLA General Hospital, Beijing, 100071, People’s Republic of China

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 January 2019 in Journal of Drug Targeting
Verified
Journal Article
Closed access
LLLi Li
Li Li
WYWu-Wei Yang
Wu-Wei Yang
DXDonggang Xu
Donggang Xu
Currently, with the rapid development of nanotechnology, novel drug delivery systems have made rapid progress, in which nanocarriers play an important role in the tumor treatment. In view of the conventional chemotherapeutic drugs with many restrictions such as non-specific systemic toxicity, short half-life and low concentration in the tumor sites, stimuli-responsive drug delivery systems can deliver anti-tumor drugs targeting to the specific sites of tumors. Owing to precise stimuli response, stimuli-responsive drug delivery systems can control drug release, so as to improve the curative effects, reduce the damage of normal tissues and organs, and decrease the side effects of traditional anti-cancer drugs. At present, according to the physicochemical properties and structures of nanomaterials, they can be divided into three categories: 1) endogenous stimuli-responsive materials, including pH, enzyme and redox responsive materials; 2) exogenous stimuli-responsive materials, such as temperature, light, ultrasound and magnetic field responsive materials; 3) multi-stimuli responsive materials. This review mainly focuses on the researches and developments of these novel stimuli-responsive drug delivery systems based on above-mentioned nanomaterials and their clinical applications.

24 January 2018 in Cancer Biology & Therapy
Verified
Journal Article
Closed access
BZBaorang Zhu
Baorang Zhu
JLJing Li
Jing Li
QXQiaosheng Xie
Qiaosheng Xie
LDLiyan Diao
Liyan Diao
LGLvhua Gai
Lvhua Gai
WYWuwei Yang
Wuwei Yang
Sarcomas are rare but malignant tumors with high risks of local recurrence and distant metastasis. Anti-angiogenic therapy is a potential strategy against un-controlled and not-organized tumor angiogenesis. We aimed to assess the safety and efficacy of apatinib, an oral tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor-2, in patients with advanced sarcoma. Thirty-one patients who received initial apatinib between September 2015 and August 2016 were retrospectively reviewed. Among them, 19 (61.3%) patients were heavily pretreated with two or more lines of cytotoxic chemotherapy. Apatinib was given at a start-dose of 425 mg qd. During therapy, 9 (29.0%) patients required dose interruption and 7 (22.6%) needed dose reduction, and the mean dosage of apatinib was 372.9 ± 68.4 mg/day. In the study cohort, one patient was treated as adjunctive therapy and 6 patients stopped treatment before radiographic response assessment. Thus, 24 patients were eligible for tumor response evaluation. The objective response rate was 33.3% and clinical benefit rate was as high as 75.0%. The progression free survival was 4.25 (95% confidence interval [CI], 2.22–5.11) months, whereas the overall survival was 9.43 (95% CI, 6.64–18.72) months. Compared with other histological subtypes, leiomyosarcoma did not show significant survival benefits. Most of the adverse events (AEs) were at grade 1 or 2. The main grade 3 AEs were hypertension (6.5%), hand foot skin reaction (6.5%), and diarrhea (3.2%). In conclusion, apatinib showed promising efficacy and acceptable safety profile in metastatic or recurrent sarcoma, giving rationale clinical evidence to conduct clinical trials.

17 December 2019 in The Oncologist
Verified
Journal Article
Open access
PDF file
BZBaorang Zhu
Baorang Zhu
YLYing Liu
Ying Liu
JLJing Li
Jing Li
LDLiyan Diao
Liyan Diao
LSLin Shao
Lin Shao
WYWuwei Yang
Wuwei Yang
Cervical carcinosarcoma is an extremely rare type of neoplasm that lacks standard of care. Preclinical and clinical evidence has suggested that cryoablation in combination with immunotherapy may result in a synergistic effect, generating a more robust immune response to distant lesions. A few clinical trials have evaluated the efficacy of such combination treatment in a variety of solid tumors, but with conflicting results. This report describes the first clinical efficacy of cryoablation followed by pembrolizumab observed in a patient with tumor mutational burden (TMB)-high metastatic cervical carcinosarcoma that was negative for programmed cell death protein 1 expression, microsatellite instability stable, and had mutations in DNA polymerase epsilon (POLE). She had achieved complete response (CR) after 3 months of pembrolizumab treatment and had maintained CR as of the time of submission of this manuscript, with a progression-free survival of 11 months and counting. The case exhibited an exceptional response to cryoablation followed by pembrolizumab, potentially attributed to mutations in POLE, which lead to an extremely high TMB. This report paves the avenue for establishing treatment regimens for patients with TMB-high cervical carcinosarcoma. Key Points: Owing to its rarity, cervical carcinosarcoma has not been well characterized, and currently, there is no standard of care for this disease. This report describes the first case of clinical efficacy of cryoablation followed by pembrolizumab observed in a patient with tumor mutational burden-high metastatic cervical carcinosarcoma. The case exhibited an exceptional response (maintained CR as of the time of submission of this article: 11 months) to cryoablation followed by pembrolizumab. This is the first POLE-mutated cervical carcinosarcoma case.

1 October 2025 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
JLJing Li
Jing Li
RLRui Liu
Rui Liu
BZBao-Rang Zhu
Bao-Rang Zhu
DWDai-Lian Wang
Dai-Lian Wang
JZJie-Min Zhou
Jie-Min Zhou
MWMaoqiang Wang
Maoqiang Wang
Objective: This study aimed to evaluate the feasibility and tolerability of arterial infusion chemotherapy embolization (AICE) in treating recurrent/metastatic soft tissue sarcoma (STS) and to explore relevant prognostic factors to tailor future individualized treatment. Methods: A total of 113 patients with recurrent/metastatic STS treated with AICE at the Fifth Medical Center of the PLA General Hospital were included in this retrospective study. The primary outcomes were progression-free survival (PFS) and overall survival (OS). Kaplan–Meier survival curves were adopted and univariate and multivariate analyses were conducted using the Cox proportional hazards model to evaluate prognostic factors. Treatment-related adverse events (TRAEs) were graded according to the Society of Interventional Radiology (SIR) standards. Results: Among the 113 patients, the median OS was 19.0 months (95% CI: 12.8– 25.3) with 2-year OS rates of 45.1%. The median PFS was 11.0 months (95% CI: 8.6– 13.4) with 2-year PFS rates of 25.7%. Objective response rate (ORR) was 37.2% (95% CI: 28.3%– 46.8%) and disease control rate (DCR) was 76.1% (95% CI: 67.1%– 83.6%). Univariate analysis revealed that tumor size, presence of distant metastasis, number of postoperative treatment regimens, pathological differentiation and neutrophil-to-lymphocyte ratio (NLR) were significantly associated with OS and PFS (P< 0.05). Multivariate Cox analysis confirmed that tumor size, distant metastasis, number of postoperative treatment regimens, pathological differentiation and short-term efficacy were independent prognostic factors for OS (P< 0.05). The most common TRAEs were pain (23.0%), transient bone marrow suppression (15.0%) and postoperative fever (6.2%). No severe or fatal adverse reactions and treatment-related mortalities were observed, demonstrating superior tolerability. Conclusion: AICE might be a feasible and well-tolerated treatment for recurrent/metastatic STS, effectively controlling disease progression and improving survival outcomes in this retrospective cohort. Further multicenter, large-scale prospective studies were needed to validate these findings and explore the combination of AICE with immunotherapy or targeted therapy to optimize treatment strategy for STS.

22 July 2025 in Science Progress
Verified
Journal Article
Open access
BZBaorang Zhu
Baorang Zhu
YLYing Liu
Ying Liu
JLJing Li
Jing Li
WYWuwei Yang
Wuwei Yang
Ovarian cancer (OC), one of the most common gynecological cancers, is usually diagnosed at an advanced stage. High-grade serous ovarian cancer (HGSOC) is a histological subtype of OC that accounts for approximately 70% of all OC cases. erb-b2 receptor tyrosine kinase 2 (ERBB2) overexpression commonly occurs in HGSOC, accounting for 12.5% of stage III and IV HGSOCs. Currently, there is no established treatment strategy for OC patients with ERBB2 amplification or ERBB2 overexpression. Whether these patients will benefit from ERBB2 inhibitors remains unclear. Herein, we report a patient with metastatic HGSOC carrying ERBB2 amplification and ERBB2 overexpression. Following progression to platinum-based chemotherapy and subsequent antiangiogenic therapies, the patient benefited from late-line pyrotinib treatment, achieving stable disease with a progression-free survival of 9.5 months. Our study provides preliminary clinical evidence supporting pyrotinib as a feasible treatment option for metastatic HGSOC patients with ERBB2 amplification and/or ERBB2 overexpression. Prospective trials of pyrotinib should be conducted in appropriately selected OC populations.